Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10271): 281-292, 2021 01 23.
Article
in En
| MEDLINE
| ID: mdl-33485453
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Pyrazoles
/
Pyrimidinones
/
Deoxycytidine
/
Enzyme Inhibitors
/
Antimetabolites, Antineoplastic
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Lancet
Year:
2021
Type:
Article
Affiliation country:
Canada